
If corroborated by longer-term studies, researchers argued the treatment could be a safe short-term treatment for patients.

If corroborated by longer-term studies, researchers argued the treatment could be a safe short-term treatment for patients.

Investigators also studied omega-6, but they found no evidence that it is involved in causing systemic lupus erythematosus (SLE).

On this episode of Managed Care Cast, Lori Timmins, PhD, and Eugene Rich, MD, discuss the findings of their interim analysis of data from the first 3 years of the Comprehensive Primary Care Plus Initiative, a large-scale effort of primary care redesign meant to improve care fragmentation among Medicare fee-for-service beneficiaries.

Advances in whole genome sequencing are helpful in linking genetic variants with diseases, but the process is more challenging in cases of rare and ultra-rare diseases.

This new investigation compared outcomes among pediatric patients with type 1 diabetes (T1D) before and after COVID-19 restrictions were imposed in Dallas County on March 15, 2020.

A randomized clinical trial examined patient quality of life in Parkinson disease (PD) when adding different adjuvant therapies to levodopa to help control dyskinesia and a flaring of symptoms during OFF periods to see if one drug class had any benefit over another.

A recent study found that older men with higher body mass index are more likely to receive a diagnosis of obstructive sleep apnea, but women are accounting for a growing number of new diagnoses.

Mantle cell lymphoma is a difficult cancer type with high relapse rates, but novel targeted approaches such as CAR T-cell therapy hold promise for more successful response rates in the future.

William Schaffner, MD, medical director at the National Foundation for Infectious Diseases (NFID), and Patsy Stinchfield, RN, MS, CPNP, president-elect of NFID, explain how COVID-19 testing developments have opened doors for developments in respiratory syncytial virus (RSV) testing.

Compared with placebo, dupilumab treatment resulted in statistically significant and meaningful symptom improvements in adults and adolescents with eosinophilic esophagitis (EoE), according to abstracts presenting findings from the 3-part LIBERTY-EoE-TREET study.

Quality measures are the lifeblood of practice transformation, but learning which ones make a difference—and how to use them to drive change—is as much an art as a science, according to 3 oncology care leaders who discussed the topic Friday at the 2022 Community Oncology Conference, presented by the Community Oncology Alliance.

Low functional status based on Duke Activity Status Instrument score was associated with higher cardiometabolic risk among individuals 45 years and older living with HIV, this new multinational cohort study found.

During a panel at the Community Oncology Alliance’s Community Oncology Conference, speakers discuss practice-level efforts to reduce cancer care disparities.

Across the studies of a new analysis, there was a significant risk difference in motor milestone response and improvement in Hammersmith Infant Neurological Examination score.

FoundationOne CDx has been approved as a companion diagnostic to identify patients with non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 alternations eligible for treatment with EGFR tyrosine kinase inhibitors.

Recent research presented at the 2022 American Academy of Allergy, Asthma & Immunology Annual Meeting examined different aspects of the use of biologics for severe asthma.

As a result of being less likely than men to receive lifesaving treatment when experiencing cardiogenic shock, women were significantly less likely to survive in the short and long term.

Christopher Phillips, MD, a rheumatologist in Kentucky, discusses some of the insurance challenges for patients confronted by prior authorization and the possible impact on their disease and quality of life.

Existing research appears to suggest these patients can be treated similarly to patients with other genetic subtypes of cutaneous melanomas.

Lalan Wilfong, MD, vice president of Payer Relations & Practice Transformation at The US Oncology Network, speaks on how use of health economics and outcomes research has benefitted patient care in the community oncology setting and where it can be further leveraged in the pursuit of value-based care.

Despite current challenges in targeting pancreatic cancer with CAR T-cells, novel targets and strategies hold promise in this difficult disease setting.

Jim Schwartz, RPh, corporate pharmacy manager, Texas Oncology, discussed pharmacy challenges regarding equitable care and distribution of specialty drugs in the community oncology setting.

A recent study found that a nurse practitioner/community health worker intervention was a feasible and acceptable strategy for addressing how social determinants of health (SDOH) and comorbidities influence chronic obstructive pulmonary disease (COPD) self-management.

Addressing avoidable emergency department (ED) utilization takes interventions in partnership with providers.

Public financial statements from 9 dermatology groups backed by private equity (PE) were analyzed by the researchers, who described a significant decrease in debt valuations of these groups both before and during the COVID-19 pandemic.

Incident end-stage kidney disease cases more than doubled among Asian individuals, and prevalent cases more than tripled for Asian, Native Hawaiian or other Pacific Islander, and Hispanic individuals.

Authors outlined advancements in chimeric antigen receptor-modified T (CAR-T) cell therapy for lung cancer, and accompanying challenges.

Sunil Verma, MD, senior vice president and global head of oncology, medical, at AstraZeneca, talks about advancements in standards of care for uncommon cancers, including cholangiocarcinoma.

A recent review examined currently approved treatments and those under investigation for mantle cell lymphoma.

Based on their findings, the investigators argue a need for more inclusive representation of patients with pulmonary arterial hypertension (PAH) across the weight spectrum.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
